Skip to main content
EuBiologics Co., Ltd. logo

EuBiologics Co., Ltd. — Investor Relations & Filings

Ticker · 206650 ISIN · KR7206650004 KO Manufacturing
Open in API
Filings indexed 425 across all filing types
Latest filing 2020-05-29 Major Shareholding Noti…
Country KR South Korea
Listing KO 206650

About EuBiologics Co., Ltd.

http://eubiologics.com/eng/

EuBiologics Co., Ltd. is a biopharmaceutical company focused on improving global public health through the development and supply of safe and effective vaccines. The company specializes in preventative vaccines against global pandemics and emerging infectious diseases, with a key product being its oral cholera vaccine. In addition to its vaccine pipeline, EuBiologics provides Contract Research and Manufacturing Organization (CRMO) services. These services cover the development and GMP-compliant production of mammalian cell and microbial-derived biopharmaceuticals, including protein-based therapeutics and antibodies. The company is committed to technological innovation and adhering to international standards to address global health challenges.

Recent filings

Filing Released Lang Actions
최대주주변경
Major Shareholding Notification Classification · 100% confidence The document is a formal regulatory filing from a Korean company (Eubiologics) announcing a change in its largest shareholder (maximum shareholder). It details the before-and-after shareholding percentages, the reason for the change (market purchase and dissolution of special relationships), and information about the new major shareholder. This type of disclosure is a standard regulatory requirement for public companies to report significant changes in ownership structure, which falls under the 'Regulatory Filings' category as it does not fit into specific categories like 'Major Shareholding Notification' (which usually refers to external investors reporting their own holdings) or 'Director's Dealing' (which refers to individual trades).
2020-05-29 Korean
최대주주변경을수반하는주식담보제공계약체결
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from a Korean company (Eubiologics) regarding a 'Stock Collateral Agreement' (주식 담보제공 계약) involving the largest shareholder. This type of disclosure, which details the pledging of shares as collateral for personal or corporate loans, falls under the category of capital structure and financing updates. Since it does not fit into specific categories like M&A or dividend announcements, and is a formal regulatory disclosure, it is classified as a Capital/Financing Update.
2020-05-29 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status of a major shareholder (Kim Deok-sang) and his special relations in the company 'Eubiologics'. This type of filing is specifically used to notify the market when an individual or entity crosses a significant ownership threshold (typically 5%), which falls under the 'Major Shareholding Notification' category.
2020-05-29 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed by an executive (Choi Byung Ho) of U-BioLogics. This type of filing is a standard regulatory disclosure for insider trading or changes in share ownership by company directors/executives, which corresponds to the 'Director's Dealing' category.
2020-05-14 Korean
분기보고서 (2020.03)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for the company '주식회사 유바이오로직스' covering the period from January 1, 2020, to March 31, 2020. It contains detailed financial statements, business descriptions, and management analysis, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2020
2020-05-14 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the share transactions (specifically a sale of shares) by an individual named Shin Young-hee, who is identified as an executive (non-standing director) of the company Eubiologics. This type of filing is a standard regulatory requirement for insider trading/shareholding disclosures, which falls under the 'Director's Dealing' category.
2020-04-03 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.